Owusu KA, Kurczewski L, Armahizer MJ, et al. - Researchers undertook this retrospective, multicenter, observational cohort study to ascertain the clinical utility as well as the safety of dexmedetomidine (DEX) vs propofol (PRO) in neurocritical care (NCC) setting. This study involved 179 patients, including 94 DEX and 85 PRO, with a median age of 58. PRO was more often used to manage agitation. For facilitating extubation, alcohol withdrawal, and sedation during frequent neurologic evaluations, DEX was more frequently used. Experts found higher mean Glasgow Coma Scale scores in DEX group. Similarity was reported in terms of duration of either infusions, mechanical ventilation, and lengths of stay. PRO was associated with a significantly higher mortality. Overall, in this cohort, distinct indications led to the use of DEX and PRO. In terms of adverse effect profiles as well as clinical results, the cohorts were largely similar.